Published in Pharmacogenomics on October 01, 2012
A pharmacogenetics service experience for pharmacy students, residents, and fellows. Am J Pharm Educ (2013) 0.86
Advancing Pharmacogenomics Education in the Core PharmD Curriculum through Student Personal Genomic Testing. Am J Pharm Educ (2016) 0.80
Transitioning Pharmacogenomics into the Clinical Setting: Training Future Pharmacists. Front Pharmacol (2016) 0.77
Knowledge, Attitude, and Perceptions of Pharmacists and Pharmacy Students towards Pharmacogenomics in Zimbabwe. Pharmacy (Basel) (2017) 0.75
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85
Pharmacogenomics in the curricula of colleges and schools of pharmacy in the United States. Am J Pharm Educ (2010) 1.77
Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ (2011) 1.62
Emergence and evolution of pharmacogenetics and pharmacogenomics in clinical pharmacy over the past 40 years. Ann Pharmacother (2007) 1.62
Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J (2005) 1.53
A genotyping exercise for pharmacogenetics in pharmacy practice. Am J Pharm Educ (2009) 1.15
Pharmacogenomics at the tipping point: challenges and opportunities. Clin Pharmacol Ther (2011) 1.06
An inservice program on pharmacogenetics to individualize drug therapy. Am J Pharm Educ (2010) 1.00
Essential nursing competencies for genetics and genomics: implications for critical care. Crit Care Nurse (2011) 0.83
Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther (2003) 1.94
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol (2002) 1.91
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther (2005) 1.35
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr (2006) 1.35
Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant (2003) 1.28
Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol (2002) 1.26
The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev (2003) 1.08
PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics (2009) 1.05
Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol (2004) 1.02
CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem (2011) 1.00
Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab Dispos (2008) 0.95
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics (2007) 0.89
The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol (2002) 0.85
Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes. J Clin Pharmacol (2005) 0.80
Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc (2012) 0.78
PharmGKB summary: gemcitabine pathway. Pharmacogenet Genomics (2014) 0.78
Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450. J Pharmacol Exp Ther (2006) 0.77
Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.76
PharmGKB summary: zidovudine pathway. Pharmacogenet Genomics (2012) 0.76